Translocation of Activator of G-protein Signaling 3 to the Golgi Apparatus in Response to Receptor Activation and Its Effect on the trans-Golgi Network

Sukru S Oner; Ali Vural; Stephen M Lanier

doi:10.1074/jbc.M112.444505

. 2013 Jun 14;288(33):24091–24103. doi: 10.1074/jbc.M112.444505

Translocation of Activator of G-protein Signaling 3 to the Golgi Apparatus in Response to Receptor Activation and Its Effect on the trans-Golgi Network^*

Sukru S Oner ¹, Ali Vural ^1,¹, Stephen M Lanier ^1,²

PMCID: PMC3745352 PMID: 23770668

Background: The AGS3·Gα_i complex is regulated by a GPCR, but downstream signaling events are unknown.

Results: Upon receptor activation, AGS3 translocates to the Golgi apparatus, where it regulates events at the TGN.

Conclusion: The AGS3·Gα_i complex serves as a signal transducer for GPCRs.

Significance: The regulated translocation of AGS3 offers unexpected mechanisms for modulating protein secretion and/or endosome recycling events at the TGN.

Keywords: G-protein-coupled Receptors (GPCR), G-proteins, Golgi, Signal Transduction, Trafficking, AGS3-Gα_i Complex, Activator of G-protein Signaling 3, GPR Motif, Secretory Pathway, trans-Golgi Network

Abstract

Group II activators of G-protein signaling play diverse functional roles through their interaction with Gα_i, Gα_t, and Gα_o via a G-protein regulatory (GPR) motif that serves as a docking site for Gα-GDP. We recently reported the regulation of the AGS3-Gα_i signaling module by a cell surface, seven-transmembrane receptor. Upon receptor activation, AGS3 reversibly dissociates from the cell cortex, suggesting that it may function as a signal transducer with downstream signaling implications, and this question is addressed in the current report. In HEK-293 and COS-7 cells expressing the α_2A/D-AR and Gα_i3, receptor activation resulted in the translocation of endogenous AGS3 and AGS3-GFP from the cell cortex to a juxtanuclear region, where it co-localized with markers of the Golgi apparatus (GA). The agonist-induced translocation of AGS3 was reversed by the α₂-AR antagonist rauwolscine. The TPR domain of AGS3 was required for agonist-induced translocation of AGS3 from the cell cortex to the GA, and the translocation was blocked by pertussis toxin pretreatment or by the phospholipase Cβ inhibitor U73122. Agonist-induced translocation of AGS3 to the GA altered the functional organization and protein sorting at the trans-Golgi network. The regulated movement of AGS3 between the cell cortex and the GA offers unexpected mechanisms for modulating protein secretion and/or endosome recycling events at the trans-Golgi network.

Introduction

Activators of G-protein signaling (AGS)³ and regulators of G-protein signaling (RGS) proteins were both discovered in functional screens for G-protein signaling modulators and essentially define a panel of biological regulators that influence signal transfer from receptor to G-protein, guanine nucleotide binding and hydrolysis and/or G-protein subunit interactions and/or serve as alternative binding partners for Gα and Gβγ independent of the classical heterotrimeric Gαβγ. AGS and RGS proteins have revealed unexpected functional diversity for the “G-switch” signaling mechanism, expanding the functional roles of G-protein subunits and perhaps identifying new opportunities for therapeutic manipulation of G-protein signaling (1–6). RGS proteins fall into several subgroups, and there are more than 30 distinct proteins that contain an RGS or an RGS-like domain in mammalian cells (2). AGS proteins generally fall into three subgroups (1, 5). Group I AGS proteins and related entities, such as Ric-8A, GIV (Girdin), and the Saccharomyces cerevisiae protein Arr4, act as non-receptor guanine nucleotide exchange factors for Gα and/or Gαβγ (7–9). Group III AGS proteins interact with Gβγ or perhaps heterotrimer (1, 10). Sato et al. (11) also recently identified three transcription factors as AGS11, -12, and -13 with apparent selectivity for Gα₁₆; however, the biochemical properties of the G-protein regulation have not yet been fully characterized, and thus it is difficult to place these three AGS proteins into Group I, II, or III.

Group II AGS proteins are defined by the presence of one or more guanine nucleotide regulatory (GPR) motifs (12), also known as GoLoco or LGN motifs (13, 14), that bind Gα-GDP free of Gβγ. Group II AGS proteins consist of seven proteins (AGS3 (GPSM1), LGN (GPSM2, AGS5), AGS4 (GPSM3), RGS12 (AGS6), Rap1Gap (transcript variant 1), RGS14, and PCP2/L7), each of which contains 1–4 GPR motifs for docking of Gα serving as alternative binding partners for specific subtypes of Gα. There are three types of Group II AGS proteins that are distinguished by the number of GPR motifs and/or the presence of defined regulatory protein domains (1, 5). AGS3 and LGN (AGS5) have four GPR motifs downstream of a tetratricopeptide repeat domain, whereas RGS12 (AGS6), RGS14, and Rap1GAP have one GPR motif plus other defined domains that act to accelerate Gα-GTP hydrolysis (1, 5).

The GPR·Gα complex is involved in an increasingly interesting set of regulatory functions that we are just beginning to understand, including roles in cell division, neuronal plasticity, autophagy, protein trafficking, hearing, morphogenesis, and the renal response to injury (15–30). Although the majority of Gα within the cell probably exists as part of the Gαβγ heterotrimer at the cell cortex, a subpopulation of Gα_i is apparently complexed with GPR proteins. This GPR·Gα signaling module is regulated by non-receptor guanine nucleotide exchange factors, such as Ric-8A and GIV (24, 31–33), with the latter entity processing signals from cell surface growth factor receptors (24). The GPR·Gα complex (AGS3·Gα_i, AGS4·Gα_i, RGS14·Gα_i) at the cell cortex is also regulated by a subgroup of G-protein-coupled receptors (34–36). Upon receptor activation, AGS3 reversibly dissociated from Gα_i at the cell cortex (34), but the trafficking of AGS3 and its regulation following receptor activation in this system is not known. In this work, we report that AGS3 reversibly translocates from the cell cortex to the Golgi apparatus (GA), and this is associated with altered functional integrity of the trans-Golgi network. The regulated translocation of AGS3 between the cell cortex and the GA offers unexpected mechanisms for modulating protein secretion, endosome recycling, and Golgi dynamics.

EXPERIMENTAL PROCEDURES

Materials

UK-14304, U0126, and pertussis toxin were obtained from Sigma. Rauwolscine hydrochloride was obtained from Carl Roth GmbH (Karlsruhe, Germany). Polyethyleneimine (PEI) was obtained from Polysciences, Inc. (Warrington, PA). All cell culture materials were obtained from Invitrogen. HEK-293 and COS-7 cells (CRL-1573 and CRL-1651, respectively) were obtained from American Type Culture Collection (Manassas, VA). Benzyl-coelenterazine was obtained from NanoLight Technology. 96-well gray OptiPlates were obtained from PerkinElmer Life Sciences. GM130 antibody (610823) was obtained from BD Biosciences. TGN46 antibody (110-40769) was obtained from Novus Biologicals (Littleton, CO). Mannosidase II antibody (ab12277) and LAMP2 antibody (ab25631) were obtained from Abcam (Cambridge, MA). AGS3 antisera were generated in the laboratory of Dr. Dzwokai Zach Ma (University of California, Santa Barbara, CA) by immunization of rabbits with a glutathione S-transferase (GST)-AGS3 fusion protein encoded by the GPR domain (Ala⁴⁶¹–Ser⁶⁵⁰) of AGS3 (26). Sialyltransferase-EGFP (ST-GFP) was generated in the laboratory of Dr. Jennifer Lippincott-Schwartz (37). All other reagents and materials were obtained as described elsewhere (34).

Cell Culture

HEK-293 and COS-7 cells were maintained in DMEM high glucose medium supplemented with 5 or 10% fetal bovine serum, respectively, in the presence of 2 mm glutamine, 100 units/ml penicillin, and 100 μg/ml streptomycin. Cells were grown in a humidified incubator in the presence of 5% CO₂ at 37 °C. Cells were transfected using PEI as described previously (34).

Real-time Bioluminescence Resonance Energy Transfer (BRET) Measurements

HEK-293 cells were seeded on 6-well plates and cultured overnight at 37 °C. Cells were transiently transfected with donor (phRluc::AGS3), acceptor (pcDNA3::Gα_i1-YFP), and pcDNA3::α_2A/D-adrenergic receptor and processed for BRET measurements as described previously (34, 35). Cells were distributed into gray 96-well OptiPlates in triplicate (∼1 × 10⁵ cells/well). Luminescence was measured in the 480- and 530-nm emission windows at 2.5-s intervals beginning immediately after the addition of coelenterazine H to the sample wells. At 150 and 270 s, UK-14304 (1 μm) and rauwolscine (10 μm) were added by injection, respectively. Signal measurements were continued for 390 s following the addition of antagonist.

Cell Imaging

HEK-293 and COS-7 cells were seeded onto sterile 25-mm polylysine-D-coated coverslips 24 h following transfection. Cells were then processed for imaging 24 h later as described elsewhere (38). Primary antibodies were used at a dilution of 1:200 in cell washing solution (137 mm NaCl, 2.6 mm KCl, 1.8 mm KH₂PO₄, 10 mm Na₂HPO₄, pH 7.4), and secondary antibodies (goat anti-rabbit AlexaFluor488 or mouse AlexaFluor594, highly cross-adsorbed, Molecular Probes) were used at a dilution of 1:2000 in cell washing solution. All antibody dilutions were centrifuged at 10,000 × g for 10 min prior to use. The nucleus was stained with 1 μg/ml DAPI at the last washing step. Slides were then mounted with glass coverslips and analyzed with a Leica CTR5500 deconvolution fluorescence microscope using a 40× or 63× oil immersion objective as described elsewhere (38). All images were obtained from approximately the middle plane of the cells. Selected enlarged images were processed by deconvolution for higher resolution using Simple PCI version 6.6.0.0 (Hamamatsu Corp., Sewickley, PA). Images were evaluated for colocalization of GA marker proteins and AGS3 by three different approaches. First, each experiment was visually examined by at least two individuals to identify and count the population of cells exhibiting clear juxtanuclear enrichment of AGS3 and overlap of the AGS3 with GA marker proteins. Cells undergoing division were not counted to avoid any nonclarity in regard to data interpretation and the GA fragmentation that occurs during mitosis. ∼100–200 individual cells expressing AGS3-GFP were examined in each experiment, and each experiment was repeated at least three times. Second, selected images were examined by scanning of fluorescence intensity across the cell using ImageJ (39). Third, images were also evaluated for colocalization using the Coloc_2 module within the Fiji image processing package (40), which provides a thresholded Pearson's correlation coefficient for pixel overlap based on the approach developed by Costes et al. (41).

In cells transfected with pEGFP::ST, the relative distribution of ST-GFP, which resides in the trans-Golgi network, was determined by counting the numbers of ST-GFP puncta in the presence and absence of agonist. Similar experiments were conducted in cells expressing ST-GFP alone or together with pcDNA3::Gα_i3 and pcDNA3::α_2A/D-AR.

Data Analysis

Data were analyzed by analysis of variance, and significant differences between groups were determined by the Tukey a posteriori test using GraphPad Prism version 4.03 for Windows (GraphPad Software, San Diego, CA).

RESULTS AND DISCUSSION

We established a platform to monitor the interaction of GPR proteins and Gα in the intact cell by BRET. This platform involves an energy donor (AGS3-Rluc) and acceptor (Gα_i-YFP). Because AGS3-Rluc may bind up to four Gα_i-YFP, the BRET signal is particularly robust (34). At least three different types of GPR·Gα_i complexes (AGS3·Gα_i, AGS4·Gα_i, and RGS14·Gα_i) are regulated by activation of a cell surface, G-protein-coupled receptor as well as by the non-receptor guanine nucleotide exchange factor Ric-8A and/or GIV (24, 33–36). Activation of the α₂-AR rapidly decreased AGS3-Rluc·Gα_i1-YFP BRET to a new steady state, which was rapidly reversed by the addition of the α₂-AR antagonist rauwolscine (Fig. 1A). Based upon previous studies, it appears that the AGS3-Rluc is “released” from its membrane site, whereas Gα_i1-YFP remains tethered to the plasma membrane (34).

FIGURE 1. — **Influence of cell surface receptor activation on the interaction of AGS3 with Gα_i1 over time and the subcellular distribution of AGS3.** A, real-time BRET between AGS3-Rluc and Gα_i1-YFP. HEK-293 cells expressing phRluc::AGS3 (10 ng), pcDNA3::Gα_i1-YFP (750 ng), and pcDNA3::α_2A/D-AR (750 ng) were processed for BRET measurements as described under “Experimental Procedures.” The α_2A/D-AR agonist UK-14304 and antagonist rauwolscine (*Rauw*) were added as indicated. These data are expressed as means ± S.E. (*error bars*) (n = 3). B, cells were transfected with AGS3-GFP (25 ng), pcDNA3::Gα_i3 (750 ng), and pcDNA3::α_2A/D-AR (750 ng) and incubated with vehicle or UK-14304 (10 μm) for 10 min and then processed for immunofluorescence image analysis as described under “Experimental Procedures.” The image presented (10× objective) is representative of multiple experiments as described under “Experimental Procedures.”

We hypothesized that the tethered AGS3 was released to play a role in signal propagation. As a first approach to test this hypothesis, we determined the subcellular location of AGS3 after its release from the cell cortex. Upon agonist treatment in HEK cells, the marked cortical distribution of AGS3 was lost in >90% of the cells (Fig. 1B), and many cells exhibited a robust juxtanuclear enrichment of AGS3 that appeared to overlap with the cis-Golgi apparatus-resident protein GM130 (Fig. 2A). Similar results were obtained in COS-7 cells (Fig. 2B). Similar results were also obtained in both HEK and COS7 cells expressing Gα_i1.⁴ The juxtanuclear localization of AGS3-GFP observed in the presence of agonist also overlapped with the trans-Golgi marker TGN46 and a marker of the luminal GA (mannosidase II) (Fig. 3). To further define the juxtanuclear localization of AGS3 observed upon the addition of agonist, we also scanned fluorescence intensities across cells for AGS3-GFP and GA marker proteins (Figs. 2 and 3). The fluorescence intensity scans indicated that AGS3 was generally enriched at the cell cortex in the absence of agonist. However, upon receptor activation, many cells exhibited a robust accumulation of AGS3 at the juxtanuclear region and spatial overlap with the GA marker proteins (Figs. 2 and 3).

FIGURE 2. — **Influence of cell surface receptor activation on the subcellular distribution of AGS3.** HEK-293 (A) or COS-7 (B) cells expressing pEGFP::AGS3 (25 ng - HEK, 100 ng - COS-7), pcDNA3::Gα_i3 (750 ng), and pcDNA3::α_2A/D-AR (750 ng) were incubated with vehicle or UK-14304 (10 μm) for 10 min and processed for fluorescent microscopy. The Golgi marker GM130 (*red*) was detected by immunofluorescence as described under “Experimental Procedures.” The images shown are representative of 10 (HEK) or three (COS-7) separate experiments. The *arrowheads* indicate juxtanuclear localization of AGS3 following receptor activation. *Bar*, 10 μm. *Bottom panels*, the relative subcellular distributions of AGS3-GFP and GM130 were quantified by fluorescence intensity scans (green, AGS3-GFP; *red*, GM130) through the cell, as indicated by the *lines* in the images and as described under “Experimental Procedures.”

FIGURE 3. — **Influence of cell surface receptor activation on the subcellular distribution of AGS3 and the GA marker proteins TGN46 and mannosidase II.** HEK-293 cells transfected with pEGFP::AGS3 (25 ng), pcDNA3::Gα_i3 (750 ng), and pcDNA3::α_2A/D-AR (750 ng) were incubated with vehicle or UK-14304 (10 μm) for 10 min and processed for fluorescent microscopy. The Golgi markers TGN46 (*trans*-Golgi network) (A) and Mann-II (luminal GA) (B) were detected by immunofluorescence as described under “Experimental Procedures.” The images shown are representative of 5–10 separate experiments. *Bar*, 10 μm. The relative subcellular distributions of AGS3-GFP and TGN46 and Mann-II were quantified by fluorescence intensity scans (*green*, AGS3-GFP; *red*, GM130) through the cell, as indicated by the *lines* in the images and as described under “Experimental Procedures.”

The degree of colocalization of AGS3 with GA marker proteins following agonist treatment was quantitatively examined in AGS3-transfected cells using the Fiji image analysis suite. The robust, juxtanuclear localization of AGS3 after agonist treatment was visually obvious in many cells, whereas some cells exhibited a more diffuse intracellular distribution of AGS3, which was clearly different from the predominantly cortical distribution in the absence of agonist (Fig. 4A). Analysis of this mixed population of cells observed in the presence of agonist yielded a thresholded Pearson's correlation coefficient for colocalization analysis with GM130 and AGS3-GFP of 0.58 ± 0.05 (n = 34) with agonist incubation versus 0.08 ± 0.04 (n = 34) with vehicle. Further colocalization analysis of these two general subpopulations of cells with the GA marker GM130 indicated that the cells with robust, juxtanuclear localization of AGS3 following agonist treatment exhibited a thresholded Pearson's correlation coefficient of 0.81 ± 0.02 (n = 16), whereas cells exhibiting a more diffuse distribution of AGS3 without any clear enrichment at the GA exhibited a thresholded Pearson's correlation coefficient of 0.37 ± 0.04 (n = 18) (Fig. 4B) This analysis indicates that agonist treatment results in clear, statistically distinct, colocalization of AGS3 with the GA marker proteins. Similar results were obtained when colocalization analysis was conducted for AGS3 and the GA marker proteins TGN46 and mannosidase II (Fig. 4B).

FIGURE 4. — **Quantitative analysis of AGS3 translocation.** HEK-293 cells expressing pEGFP::AGS3 (25 ng), pcDNA3::Gα_i3 (750 ng), and pcDNA3::α_2A/D-AR (750 ng) were incubated with vehicle or UK-14304 (10 μm) for 10 min and processed for fluorescent microscopy. A, representative image of cells incubated with the agonist UK-14304, illustrating two populations of cell response. The *white arrowheads* indicate cells exhibiting a robust, juxtanuclear localization of AGS3-GFP after agonist treatment that was visually obvious. The *red arrowheads* indicate cells exhibiting a more diffuse intracellular distribution of AGS3-GFP. B, quantitative colocalization analysis was conducted using the Fiji image processing suite to generate thresholded Pearson's correlation coefficients for vehicle and for cells incubated with the agonist UK-14304 as described under “Experimental Procedures.” Two general subpopulations of cells were identified following agonist incubation, and each population was evaluated for colocalization of AGS3-GFP and GA marker proteins. The *white bars* correspond to the subpopulation of cells exhibiting a robust, juxtanuclear localization of AGS3 after agonist treatment. The *red bars* correspond to the second subpopulation of cells as described under “Experimental Procedures.” C, the agonist-induced translocation of AGS3-GFP to the Golgi apparatus was determined by visual examination of spectral overlap between AGS3 and the GA marker proteins as described under “Experimental Procedures” (n = 3). Data are expressed as means ± S.E. (*error bars*) as described under “Experimental Procedures.” *, p < 0.0001 *versus* vehicle. #, p < 0.0001. The *numbers above* the *bars* in *parentheses* indicate the number of AGS3-GFP-expressing cells examined.

The population of agonist-treated cells exhibiting the lower thresholded Pearson's correlation coefficient (Fig. 4, A and B) probably reflects a graded response that may represent an intermediate step in translocation of AGS3 to the juxtanuclear region or represent other trafficking pathways for AGS3 (19, 23, 24, 38). For the purposes of this current study, we focused on the population of cells exhibiting the robust, juxtanuclear enrichment of AGS3 overlapping with GA marker proteins as defined by visual examination and/or thresholded Pearson's correlation coefficients greater than 0.7, which represented ∼50% of the cells expressing transfected AGS3 (Fig. 4, B and C). Analysis of enlarged fluorescent images with the three GA marker proteins and AGS3-GFP by deconvolution indicated that the translocated AGS3-GFP generally had strong spatial colocalization with TGN46, exhibiting a tubero-vesicular appearance perhaps related to protein secretion at the trans face of the GA (Figs. 2 and 3). Although there is clear overlap of AGS3-GFP with the GA marker proteins, there are distinct areas where the GA marker proteins GM130 and Mann-II do not overlap with AGS3, indicating that AGS3 may translocate to specific subcompartments within the GA (Figs. 2 and 3). Although there are many different organelles and functional compartments that position themselves at juxtanuclear sites, the clear spatial overlap with the three GA marker proteins is consistent with translocation of AGS3 to the GA following receptor activation. We also examined the potential distribution of AGS3 among early endosomes (EEA1), lysosomes (LAMP2), and the endoplasmic reticulum (calnexin). The subcellular distribution of these three organelle markers is much broader than the juxtanuclear localization of AGS3 observed following agonist treatment (Fig. 5).⁴

FIGURE 5. — **Comparative subcellular distribution for AGS3 and markers for early endosomes or lysosomes following receptor activation.** HEK-293 cells expressing pEGFP::AGS3 (25 ng), pcDNA3::Gα_i3 (750 ng), and pcDNA3::α_2A/D-AR (750 ng) were incubated with vehicle or UK-14304 (10 μm) for 10 min and processed for fluorescent microscopy as described under “Experimental Procedures.” The early endosome marker EEA1 (A) and lysosome marker LAMP2 (B) were detected by immunofluorescence as described under “Experimental Procedures.” The images shown are representative of three separate experiments. The relative subcellular distributions of AGS3-GFP and EEA1 and LAMP2 were quantified by fluorescence intensity scans (*green*, AGS3-GFP; *red*, EEA1 or LAMP2) through the cell as indicated by the *lines* in the images and as described under “Experimental Procedures.”

We initiated a series of experiments to understand the mechanism of AGS3 translocation and to further test our hypothesis. We first determined the time course for the translocation of AGS3 to the GA. AGS3-GFP translocation to the GA was observed within 30 s of the agonist addition and was maintained in GA for at least 30 min (Fig. 6A). The percentages of AGS3-GFP-expressing cells exhibiting agonist-induced translocation of AGS3 to the GA at different time points were 31.6 ± 2.7% (thresholded Pearson's correlation coefficient = 0.88 ± 0.02, n = 4) (0.5 min), 39.4 ± 1.2% (thresholded Pearson's correlation coefficient = 0.87 ± 0.03, n = 5) (1 min), 49 ± 2% (thresholded Pearson's correlation coefficient = 0.84 ± 0.03, n = 4) (2 min), and 46.5 ± 2.8%, (Pearson's correlation coefficient = 0.81 ± 0.33, n = 6) (30 min). The spatial overlap of AGS3 with the GA marker protein GM130 was also observed by fluorescence intensity scanning across individual cells (Fig. 6A, bottom).

FIGURE 6. — **Time course and mechanisms involved with the translocation of AGS3 to the Golgi apparatus.** A, HEK-293 cells expressing pEGFP::AGS3 (25 ng), pcDNA3::Gα_i3 (750 ng), and pcDNA3::α_2A/D-AR (750 ng) were incubated with UK-14304 (1 μm) for different time periods and processed for fluorescent microscopy. The images shown are representative of three separate experiments. The *arrowheads* indicate juxtanuclear localization of AGS3 following receptor activation. *Red*, GM130. *Bottom*, the relative subcellular distributions of AGS3-GFP and GM130 were quantified by fluorescence intensity scans (green, AGS3-GFP; red, GM130) through the cell, as indicated by the *lines* in the images and as described under “Experimental Procedures.” B, *left*, agonist-induced translocation of AGS3-GFP to the Golgi apparatus as determined by co-localization with GM130. Reversibility of the UK-14304-induced translocation of AGS3 was assessed by the addition of the antagonist rauwolscine (*Rauw*) (10 μm) following a 10-min incubation of the cells with UK-14304 (1 μm). Rauwolscine incubation was continued for 10 min, and then the cells were processed for fluorescent microscopy as described under “Experimental Procedures.” Another group of cells were treated with vehicle or 100 ng/ml pertussis toxin for 16 h prior to incubation with agonist. Data are expressed as means ± S.E. (*error bars*) (n = 3–7). *Middle*, influence of the phospholipase C inhibitor U73122 on agonist-induced translocation of AGS3 to the Golgi apparatus as determined by co-localization with GM130. HEK-293 cells expressing pEGFP::AGS3 (25 ng), pcDNA3::Gα_i3 (750 ng), and pcDNA3::α_2A/D-AR (750 ng) were pretreated with U73122 (10 μm) or an inactive analog U73343 (10 μm) for 20 min prior to the addition of the α_2A/D-AR agonist UK-14304. Incubation with agonist was continued for 10 min before the cells were processed for image analysis. Data are expressed as means ± S.E. (n = 3). *Right*, quantitative analysis of cells exhibiting juxtanuclear AGS3-GFP co-localization with GM130. HEK-293 cells expressing pEGFP::AGS3 (25 ng), pcDNA3::Gα_i3 (750 ng), and pcDNA3::α_2A/D-AR (750 ng) were incubated with vehicle or brefeldin A (*BFA*) (10 μg/ml) for 30 min, and agonist (UK-14304, 1 μm) was then added with incubation continued for 10 min. GM130 (*red*) was detected by immunofluorescence. Data are expressed as means ± S.E. (n = 3). *, p < 0.0001 compared with control value in the absence of agonist. #, p < 0.0001 compared with value obtained in the presence of agonist. C, *left*, agonist-induced translocation of AGS3-GFP to the juxtanuclear area. HEK-293 cells expressing pEGFP::AGS3 (25 ng), pcDNA3::Gα_i3 (750 ng), and pcDNA3::α_2A/D-AR (750 ng) were pretreated with vehicle or U0126 (20 μm) for 1 h. Cells were then treated with UK-14304 for 10 min and processed for image analysis. *Right*, subcellular distribution of an AGS3 construct in which 24 serine/threonine residues in the GPR domain were mutated to alanine (*AGS3-PM*). HEK-293 cells expressing pEGFP::AGS3-WT (25 ng) or pEGFP::AGS3-PM (25 ng) in the presence of pcDNA3::Gα_i3 (750 ng) and pcDNA3::α_2A/D-AR (750 ng) were treated with the agonist UK-14304 for 10 min and processed for image analysis. Data are expressed as means ± S.E. (n = 3). PM, phosphomutant. In B and C, the *numbers above* the *bars* in *parentheses* indicate the number of AGS3-GFP-expressing cells examined.

We then asked if agonist-induced translocation of AGS3 to the GA was reversible. In this series of experiments, cells were first incubated with the α₂-AR UK-14304 (1 μm) for 10 min to induce AGS3 release and translocation. At this point, the α₂-AR antagonist rauwolscine (10 μm) was added for 10 min with subsequent processing of the cells for visualization. As indicated in Fig. 6B, the GA translocation of AGS3 was reversed by the receptor antagonist. We also asked if pertussis toxin treatment, which ADP-ribosylates Gα_i, effectively uncoupling it from the receptor, altered the release and translocation of AGS3. The agonist-induced translocation of AGS3 to the GA was completely blocked by pertussis toxin treatment (Fig. 6B). These data are consistent with the reversibility of the effect of receptor activation on AGS3-Rluc·Gα_i1-YFP BRET (Fig. 1) and its sensitivity to pertussis toxin (34).

We then further investigated various signaling pathways to define the mechanisms of AGS3 translocation. The agonist-induced translocation of AGS3 to the GA was completely blocked by inhibition of phospholipase Cβ with U73122 (Fig. 6B). The effect of U73122 was specific, because its inactive analog U73343 had no effect (Fig. 6B). Furthermore, the agonist-induced translocation of AGS3 to the juxtanculear region was not observed following treatment of cells with brefeldin A, which disrupts the structure of the GA (Fig. 6B). The precise mechanism by which phospholipase Cβ may regulate this transport event is not clear. Although U73122 is typically used as a phospholipase Cβ inhibitor, the molecule may have a number other actions that contribute to its pharmacological profile (42). Nevertheless, U73122 should be a useful tool to dissect the mechanisms involved in AGS3 translocation going forward.

The subcellular distribution of AGS3 and its interaction with Gα may be influenced by AGS3 phosphorylation (26, 63). However, a similar agonist-induced translocation of AGS3 to the GA was observed for an AGS3 construct in which 24 serine or threonine residues in the GPR domain were mutated to alanine to disrupt phosphorylation (Fig. 6C) (26). The agonist-induced translocation of AGS3 to the GA was also not altered by the MEK inhibitor U0126 (Fig. 6C).

To further dissect the mechanism of agonist-induced translocation of AGS3 to the GA, we examined the role of the AGS3 TPR and GPR domains. Both the TPR and GPR domains of AGS3 are important determinants of its subcellular distribution (34, 38, 43). Interaction of Gα_i with the GPR domains stabilizes AGS3 and other GPR proteins at the cell cortex, where it senses activation of a cell surface receptor (34–36). We first asked if GPR proteins lacking TPR domains (Fig. 7A) exhibited a similar agonist-induced translocation to the GA. The transcript variant AGS3-SHORT lacks the TPR domain but contains three GPR motifs (43). AGS4 is a group II AGS protein that has three GPR motifs and lacks a TPR domain (44). Although both AGS3-SH and AGS4 interact with Gα_i and are stabilized at the cell cortex, where they sense receptor activation (34, 35), neither protein was translocated to the GA upon receptor activation (Fig. 7A). Agonist-induced translocation of AGS3 to the GA was not observed for AGS3-Q/A-GFP (Figs. 7A), which cannot bind Gα_i and thus is not stabilized at the cell surface, where it can sense receptor activation (34, 38).

FIGURE 7. — **Influence of the TPR domain of AGS3 on the agonist-induced translocation of AGS3 to the Golgi apparatus.** A, *left*, schematic representation of AGS proteins. AGS3-Q/A is an AGS3 mutant with single residue mutations in each of the four GPR motifs (GPR1-Q488A, GPR2-Q541A, GPR3-Q589A, and GPR4-Q623A) that disrupt Gα_i binding to the individual GPR motif. *Right*, quantitative analysis of cells exhibiting juxtanuclear AGS3-GFP co-localization with GM-130. HEK-293 cells expressing pcDNA3::Gα_i3 (750 ng), pcDNA3::α_2A/D-AR (750 ng) and pEGFP::AGS3 (25 ng), pEGFP::AGS3-Q/A (25 ng), pEGFP::AGS4 (25 ng), or pEGFP::AGS3-SHORT (AGS3-SH-GFP) (25 ng) were incubated with vehicle or UK-14304 (10 μm) for 10 min and processed for fluorescent microscopy as described under “Experimental Procedures.” *, p < 0.0001 compared with the control value in the absence of agonist. B and C, quantitative analysis of cells exhibiting juxtanuclear AGS3-GFP co-localization with GM-130. HEK-293 cells expressing pcDNA3::Gα_i3 (750 ng), pcDNA3::α_2A/D-AR (750 ng), and pEGFP::AGS3-WT or AGS3 constructs (25 ng) with progressive deletion of individual TPR motifs (B) or with single amino acid mutations of conserved residues within individual TPR motifs (C) were incubated with vehicle or UK-14304 (10 μm) for 10 min and processed for fluorescent microscopy as described under “Experimental Procedures.” GM130 (*red*) was detected by immunofluorescence. In B, 800 AGS3-GFP-expressing cells were examined for subcellular distribution determination for each AGS3-GFP construct. Data are expressed as means ± S.E. (*error bars*) (n = 3–5). *, p < 0.0001 compared with UK-14304-treated control. For C, G50F (TPR1), G90F (TPR2), G130F (TPR3), G270F (TPR6). For A and C, the *numbers above* the *bars* in *parentheses* indicate the number of AGS3-GFP-expressing cells examined.

As noted above, neither AGS4 or AGS3-SHORT translocated to the GA upon receptor activation, suggesting that the TPR domain was required for accumulation of AGS3 at the GA upon the addition of agonist. We thus addressed the role of individual TPR motifs in GA translocation of AGS3 by determining the subcellular distribution of AGS3-GFP constructs lacking individual TPR motifs. AGS3 lacking TPR1 exhibited agonist-induced translocation similar to wild type AGS3. However, deletion of both TPR1 and TPR2 markedly reduced the agonist-induced accumulation of AGS3 in the GA (Fig. 7B). Similar results were observed with the progressive deletion of TPR3–7 (Fig. 7B). These data suggested that TPR2 or perhaps broader structural organization within the TPR domain was a key factor in the regulated translocation of AGS3. To further address this question, we generated AGS3-GFP constructs with single amino acid mutations of conserved residues within individual TPR motifs (38). Mutation of a single conserved G within TPR2 (G90F), but not TPR1 (G50F), TPR3 (G130F), or TPR6 (G270F), markedly reduced the agonist-induced accumulation of AGS3 in the GA (Fig. 7C). Thus, TPR2 appears to be a key site for engagement with regulatory binding partners for AGS3 in the GA or in the context of the transport process.

We next asked if endogenous AGS3 also translocated to the GA. For endogenous AGS3, ∼200 cells were examined in each of three experiments for localization of AGS3 and the GA marker protein GM130 with and without agonist treatment (Fig. 8). Upon receptor activation, endogenous AGS3 was clearly translocated to a juxtanuclear region, where it also localized with GM130 (Fig. 8). Each of the fluorescence intensity scans for Fig. 8 actually spans two cells, one of which exhibited AGS3 translocation to the GA and one of which did not. Of the 735 cells examined, ∼47.4 ± 2.4% exhibited GA localization of AGS3 following agonist treatment. The colocalization of endogenous AGS3 with GM130 was also examined by quantitative image analysis. The thresholded Pearson's correlation coefficient for AGS3 and GM130 in responsive cells was 0.9 ± 0.02 (n = 10).

FIGURE 8. — **Subcellular distribution of endogenous AGS3 after receptor activation.** HEK-293 cells expressing pcDNA3::Gα_i3 (750 ng) and pcDNA3::α_2A/D-AR (750 ng) were incubated with vehicle or UK-14304 (10 μm) for 10 min and processed for fluorescent microscopy as described under “Experimental Procedures.” The images shown are representative of over five separate experiments. Endogenous AGS3 was detected with affinity-purified antibody generated against a GST-AGS3 fusion protein encoding the GPR domain (Ala⁴⁶¹–Ser⁶⁵⁰) of AGS3. GM130 was detected by immunofluorescence as described under “Experimental Procedures.” The *arrowheads* indicate juxtanuclear localization of AGS3 following receptor activation. The relative subcellular distributions of endogenous AGS3 and GM130 were quantified by fluorescence intensity scans (*green*, AGS3-GFP; *red*, GM130) through the cell as indicated by the *lines* in the images and as described under “Experimental Procedures.”

These data support the previous observations that the AGS3-Gα_i signaling module at the cell surface senses receptor activation, and then the two binding partners dissociate (34). It is not known if the receptor directly couples to AGS3-Gα_i or whether the coupling is indirect within the context of a larger signaling complex (see discussion in Ref. 34). Subsequent to release from the cell cortex, AGS3 is found in the GA. Receptor-mediated translocation of AGS3 is of great interest because it may have functional consequences with respect to protein secretion and trafficking through the GA, as suggested earlier by Groves et al. (18). Groves et al. reported that AGS3 overexpression redistributed TGN-localized proteins and modulated protein trafficking from the GA to the plasma membrane. siRNA-mediated knockdown of AGS3 also led to dispersal of TGN-localized proteins, including TGN46 and the mannose 6-phosphate receptor. These data suggest that AGS3 dynamically regulates events at the TGN.

We thus examined the functional consequences of agonist-induced translocation of endogenous AGS3 to the GA by monitoring the distribution of the specific trans-Golgi-resident protein sialyltransferase tagged with GFP (ST-GFP). In the absence of agonist, ST-GFP was tightly focused in the GA. However, agonist treatment (3-h incubation) disrupted the focused localization of ST-GFP with apparent vesiculation and fragmentation of the trans-Golgi network (Fig. 9, A and B). We also examined the distribution of AGS3 and the GA marker proteins GM130 and TGN46 following incubation of cells with agonist for 3 h. In general, the juxtanuclear localization of endogenous AGS3 or transfected AGS3-GFP was also observed following a 3-h incubation with agonist (Fig. 10). However, in some instances, the juxtanuclear localization of AGS3 following longer incubation with agonist was more heterogeneous and not as compact as observed with shorter incubation times, consistent with an effect on overall all GA architecture. In addition, the immunofluorescence intensity for TGN46 in the juxtanuclear region was consistently lower in cells exhibiting apparent GA accumulation of AGS3 following a 3-h agonist treatment (Fig. 10). This is most evident by comparing the intensity of juxtanuclear TGN46 in cells exhibiting apparent juxtanuclear accumulation of AGS3 with surrounding cells in Fig. 10A. The magnitude of the decrease in immunofluorescence intensity for TGN46 in cells exhibiting GA translocation of AGS3-GFP after a 3-h incubation with agonist varied as indicated in the different panels shown in Fig. 10A. The loss of TGN46, which is a marker of recycling endosomes, would suggest an effect of AGS3 on the cycling process and/or vesicle sorting at the TGN. In contrast to the observations with TGN46, the immunofluorescence intensity for GM130 was similar across all cells (Fig. 10, A and B).

FIGURE 9. — **AGS3 translocation to the Golgi apparatus and distribution of the *trans*-Golgi protein ST-GFP.** HEK-293 cells expressing pEGFP::ST (sialyltransferase) (ST-GFP) (50 ng) alone or together with pcDNA3::Gα_i3 (750 ng) and pcDNA3::α_2A/D-AR (750 ng) were incubated with agonist UK-14304 (10 μm) for 3 h and processed for fluorescent microscopy as described under “Experimental Procedures.” The images shown are representative of 3–5 separate experiments. B, quantitative analysis of percentage of the cells with the indicated vesicle numbers. Data are expressed as means ± S.E. (*error bars*) (n = 3). *, p < 0.0001 compared with control value in the absence of agonist. The *numbers above* the *bars* indicate the number of ST-GFP-expressing cells examined.

FIGURE 10. — **AGS3 translocation to the Golgi apparatus following 3-h incubation with vehicle or the α₂-adrenergic receptor agonist UK-14304.** A, HEK-293 cells expressing pEGFP::AGS3 (25 ng) together with pcDNA3::Gα_i3 (750 ng) and pcDNA3::α_2A/D-AR (750 ng) were incubated with vehicle or agonist UK-14304 (10 μm) for 3 h and processed for fluorescence microscopy. The Golgi marker protein TGN46 was detected by immunofluorescence. Three different image fields are presented for cells incubated with agonist. B, HEK-293 cells expressing pcDNA3::Gα_i3 (750 ng) and pcDNA3::α_2A/D-AR (750 ng) were incubated with vehicle or agonist UK-14304 (10 μm) for 3 h and processed for fluorescence microscopy. Endogenous AGS3 (*red*) and the Golgi marker protein GM130 (*green*) were detected by immunofluorescence as described under “Experimental Procedures.” Two different *image fields* are presented for cells incubated with agonist. The *lower image panel* was generated in parallel from HEK-293 cells transfected with pEGFP::AGS3 (25 ng) together with pcDNA3::Gα_i3 (750 ng) and pcDNA3::α_2A/D-AR (750 ng). The images shown in A and B are representative of three separate experiments.

The distribution of TGN46 within the cell is actually in apparent constant flux as it moves within the recycling endosome pathway. The kinetics of this flux are such that under standard conditions, the protein is accumulated at the trans-Golgi, providing a robust signal as a TGN marker. Upon disruption of the TGN or interference with the recycling endosome pathway, the accumulation of TGN46 at the trans-Golgi network is not observed because the protein is apparently dispersed through the cell, resulting in a loss of the robust immunofluorescence signal at the TGN. The reduction in the accumulation of TGN46 at the TGN following 3-h incubation with the α₂-AR agonist UK-14304 probably reflects an effect on vesicle cycling events at the TGN rather than a reduction of TGN46 protein in the cell. (TGN46 dispersal also occurs with cell division, brefeldin A, and other interventions that disrupt the TGN. TGN46 immunoblots from vehicle- or agonist-treated cells indicated no marked change in the levels of TGN46 following agonist treatment, consistent with its apparent dispersal rather than actual loss of the protein).⁴

These data are consistent with the hypothesis that the AGS3·Gα_i complex acts as a signal transducer mediating downstream functional responses to activation of cell surface receptors. A primary downstream target of AGS3 is the trans-Golgi network, where it appears to modulate protein secretion and/or endosome recycling. The first suggestion of a direct effect of AGS3 on GA function was the report by Groves et al. (18), indicating that either a reduction or an increase in AGS3 expression resulted in altered GA structural organization. In addition, Groves et al. (18) reported regulation of the trafficking of a specific subgroup of proteins to the cell surface following siRNA-mediated reduction of AGS3. These data and the present work suggest that the receptor activation-induced dissociation of an AGS3-Gα_i complex with the subsequent docking of AGS3 at the GA provides an unexpected platform for regulation of events at the GA.

However, although altered AGS3 expression may influence GA structure and/or the movement of proteins through the secretory pathway, the observed effect of agonist on the TGN organization reported in the present paper may not be solely due to AGS3 translocation to the GA. The regulation of protein processing and movement in the secretory pathway is complex and involves multiple regulatory mechanisms and checkpoints. Specific subtypes of Gα_i and Gβγ and various proteins that interact and regulate G-proteins are found in the GA, where they may influence basal and regulated processing of proteins through the secretory pathway (45–61). Several different factors may act in concert to influence membrane dynamics and vesicle recycling, sorting, and budding at the TGN.

Activation of M2 and M3 muscarinic receptors, which couple to heterotrimeric G_i/o and G_q, respectively, leads to translocation of specific Gγ subtypes to the GA as Gβγ complexes (57). As reported for AGS3 in the present paper, the translocation of Gβγ to the GA leads to alterations in TGN organization and the processing of proteins through the secretory pathway (57). Protein kinase D and phospholipase Cβ, both of which are activated by Gβγ, play central roles in transport vesicle budding at the trans-Golgi network. Gβγ-mediated regulation of protein kinase D leads to GA fragmentation (49, 59–61). The Gβγ-mediated regulation of GA fragmentation may involve activation of phospholipase Cβ as it is blocked by U73122 (57, 60, 61). It is not clear if the phospholipase Cβ involved resides at the plasma membrane or within the GA, but the diacylglycerol generated upon its activation is postulated to be important for protein kinase D activation in the GA and the subsequent shuttling of proteins out of the trans-Golgi network.

Thus, AGS3, Gα, and Gβγ can all influence the structure and function of the GA. The role of AGS3 in these regulatory events is of particular interest. Via its GPR motifs, translocated AGS3 may regulate the interaction of Golgi-resident Gα with translocated Gβγ, increasing the availability of free Gβγ for effector engagement in the GA. Alternatively, the translocated AGS3 may interact with specific TPR-binding partners in the GA to regulate GA function independent of any GA-resident Gα or Gβγ translocated to the GA.

The regulated positioning of AGS3 in the GA adds an unexpected additional mechanism for dynamic and reversible regulation of protein trafficking through the secretory pathway. As noted above, AGS3 is implicated in various functional responses in several different tissues or cell types, suggesting that it is regulating a basic cellular process. Perhaps the regulation of GA dynamics and the secretory pathway is a target for AGS3 shared across multiple tissues.

Acknowledgments

We thank Dr. Dzwokai Zach Ma (University of California, Santa Barbara, CA) for AGS3 antisera and the AGS3 construct containing GPR Ser/Thr mutations (26), Dr. Jennifer Lippincott-Schwartz (National Institutes of Health, Bethesda, MD) for pEGFP::ST plasmid, Dr. Joe Blumer for pEGFP::AGS4 and for helpful discussions, and Dr. Michel Bouvier (University of Montreal) for support and collaboration on the development of the BRET assay for monitoring GPR-Gα_i interactions. We also thank Dr. Gregory G. Tall (University of Rochester School of Medicine and Dentistry) for pcDNA3.1::Gα_i1-YFP (pos. 122) plasmid, which was generated by Dr. Scott Gibson (62). We also appreciate the continued technical assistance provided by Heather Bainbridge.

This work was supported, in whole or in part, by National Institutes of Health Grant DA025896 (to S. M. L.).

⁴

S. S. Oner and S. M. Lanier, unpublished observations.

The abbreviations used are:

AGS: activator(s) of G-protein signaling
RGS: regulator(s) of G-protein signaling
GPR: G-protein regulatory
GA: Golgi apparatus
ST: sialyltransferase
BRET: bioluminescence resonance energy transfer
EGFP: enhanced GFP
TGN: trans-Golgi network.

REFERENCES

1. Blumer J. B., Smrcka A. V., Lanier S. M. (2007) Mechanistic pathways and biological roles for receptor-independent activators of G-protein signaling. Pharmacol. Ther. 113, 488–506 [DOI] [PMC free article] [PubMed] [Google Scholar]
2. Hollinger S., Hepler J. R. (2002) Cellular regulation of RGS proteins. Modulators and integrators of G protein signaling. Pharmacol. Rev. 54, 527–559 [DOI] [PubMed] [Google Scholar]
3. Regner K. R., Nozu K., Lanier S. M., Blumer J. B., Avner E. D., Sweeney W. E., Jr., Park F. (2011) Loss of activator of G-protein signaling 3 impairs renal tubular regeneration following acute kidney injury in rodents. FASEB J. 25, 1844–1855 [DOI] [PMC free article] [PubMed] [Google Scholar]
4. Sato M., Jiao Q., Honda T., Kurotani R., Toyota E., Okumura S., Takeya T., Minamisawa S., Lanier S. M., Ishikawa Y. (2009) Activator of G protein signaling 8 (AGS8) is required for hypoxia-induced apoptosis of cardiomyocytes. Role of G βγ and connexin 43 (CX43). J. Biol. Chem. 284, 31431–31440 [DOI] [PMC free article] [PubMed] [Google Scholar]
5. Blumer J. B., Sadik Oner S., Lanier S. M. (2012) Acta Physiol. 204, 202–218 [DOI] [PubMed] [Google Scholar]
6. Kimple A. J., Bosch D. E., Giguère P. M., Siderovski D. P. (2011) Regulators of G-protein signaling and their Gα substrates. Promises and challenges in their use as drug discovery targets. Pharmacol. Rev. 63, 728–749 [DOI] [PMC free article] [PubMed] [Google Scholar]
7. Tall G. G., Krumins A. M., Gilman A. G. (2003) Mammalian Ric-8A (synembryn) is a heterotrimeric Gα protein guanine nucleotide exchange factor. J. Biol. Chem. 278, 8356–8362 [DOI] [PubMed] [Google Scholar]
8. Garcia-Marcos M., Kietrsunthorn P. S., Pavlova Y., Adia M. A., Ghosh P., Farquhar M. G. (2012) Functional characterization of the guanine nucleotide exchange factor (GEF) motif of GIV protein reveals a threshold effect in signaling. Proc. Natl. Acad. Sci. U.S.A. 109, 1961–1966 [DOI] [PMC free article] [PubMed] [Google Scholar]
9. Lee M. J., Dohlman H. G. (2008) Coactivation of G protein signaling by cell-surface receptors and an intracellular exchange factor. Curr. Biol. 18, 211–215 [DOI] [PMC free article] [PubMed] [Google Scholar]
10. Sato M., Cismowski M. J., Toyota E., Smrcka A. V., Lucchesi P. A., Chilian W. M., Lanier S. M. (2006) Identification of a receptor-independent activator of G protein signaling (AGS8) in ischemic heart and its interaction with Gβγ. Proc. Natl. Acad. Sci. U.S.A. 103, 797–802 [DOI] [PMC free article] [PubMed] [Google Scholar]
11. Sato M., Hiraoka M., Suzuki H., Bai Y., Kurotani R., Yokoyama U., Okumura S., Cismowski M. J., Lanier S. M., Ishikawa Y. (2011) Identification of transcription factor E3 (TFE3) as a receptor-independent activator of Gα16. Gene regulation by nuclear Gα subunit and its activator. J. Biol. Chem. 286, 17766–17776 [DOI] [PMC free article] [PubMed] [Google Scholar]
12. Takesono A., Cismowski M. J., Ribas C., Bernard M., Chung P., Hazard S., 3rd, Duzic E., Lanier S. M. (1999) Receptor-independent activators of heterotrimeric G-protein signaling pathways. J. Biol. Chem. 274, 33202–33205 [DOI] [PubMed] [Google Scholar]
13. Ponting C. P. (1999) Raf-like Ras/Rap-binding domains in RGS12- and still-life-like signalling proteins. J. Mol. Med. 77, 695–698 [DOI] [PubMed] [Google Scholar]
14. Siderovski D. P., Diversé-Pierluissi M., De Vries L. (1999) The GoLoco motif. A Gαi/o binding motif and potential guanine-nucleotide exchange factor. Trends Biochem. Sci. 24, 340–341 [DOI] [PubMed] [Google Scholar]
15. Blumer J. B., Lord K., Saunders T. L., Pacchioni A., Black C., Lazartigues E., Varner K. J., Gettys T. W., Lanier S. M. (2008) Activator of G protein signaling 3 null mice. I. Unexpected alterations in metabolic and cardiovascular function. Endocrinology 149, 3842–3849 [DOI] [PMC free article] [PubMed] [Google Scholar]
16. Bowers M. S., Hopf F. W., Chou J. K., Guillory A. M., Chang S. J., Janak P. H., Bonci A., Diamond I. (2008) Nucleus accumbens AGS3 expression drives ethanol seeking through Gβγ. Proc. Natl. Acad. Sci. U.S.A. 105, 12533–12538 [DOI] [PMC free article] [PubMed] [Google Scholar]
17. Bowers M. S., McFarland K., Lake R. W., Peterson Y. K., Lapish C. C., Gregory M. L., Lanier S. M., Kalivas P. W. (2004) Activator of G protein signaling 3. A gatekeeper of cocaine sensitization and drug seeking. Neuron 42, 269–281 [DOI] [PMC free article] [PubMed] [Google Scholar]
18. Groves B., Gong Q., Xu Z., Huntsman C., Nguyen C., Li D., Ma D. (2007) A specific role of AGS3 in the surface expression of plasma membrane proteins. Proc. Natl. Acad. Sci. U.S.A. 104, 18103–18108 [DOI] [PMC free article] [PubMed] [Google Scholar]
19. Nadella R., Blumer J. B., Jia G., Kwon M., Akbulut T., Qian F., Sedlic F., Wakatsuki T., Sweeney W. E., Jr., Wilson P. D., Lanier S. M., Park F. (2010) Activator of G protein signaling 3 promotes epithelial cell proliferation in PKD. J. Am. Soc. Nephrol. 21, 1275–1280 [DOI] [PMC free article] [PubMed] [Google Scholar]
20. Yao L., McFarland K., Fan P., Jiang Z., Inoue Y., Diamond I. (2005) Activator of G protein signaling 3 regulates opiate activation of protein kinase A signaling and relapse of heroin-seeking behavior. Proc. Natl. Acad. Sci. U.S.A. 102, 8746–8751 [DOI] [PMC free article] [PubMed] [Google Scholar]
21. Yao L., McFarland K., Fan P., Jiang Z., Ueda T., Diamond I. (2006) Adenosine A2a blockade prevents synergy between μ-opiate and cannabinoid CB1 receptors and eliminates heroin-seeking behavior in addicted rats. Proc. Natl. Acad. Sci. U.S.A. 103, 7877–7882 [DOI] [PMC free article] [PubMed] [Google Scholar]
22. Willard F. S., Zheng Z., Guo J., Digby G. J., Kimple A. J., Conley J. M., Johnston C. A., Bosch D., Willard M. D., Watts V. J., Lambert N. A., Ikeda S. R., Du Q., Siderovski D. P. (2008) A point mutation to Gαi selectively blocks GoLoco motif binding. direct evidence for Gα·GoLoco complexes in mitotic spindle dynamics. J. Biol. Chem. 283, 36698–36710 [DOI] [PMC free article] [PubMed] [Google Scholar]
23. Pattingre S., De Vries L., Bauvy C., Chantret I., Cluzeaud F., Ogier-Denis E., Vandewalle A., Codogno P. (2003) The G-protein regulator AGS3 controls an early event during macroautophagy in human intestinal HT-29 cells. J. Biol. Chem. 278, 20995–21002 [DOI] [PubMed] [Google Scholar]
24. Garcia-Marcos M., Ear J., Farquhar M. G., Ghosh P. (2011) A GDI (AGS3) and a GEF (GIV) regulate autophagy by balancing G protein activity and growth factor signals. Mol. Biol. Cell 22, 673–686 [DOI] [PMC free article] [PubMed] [Google Scholar]
25. Chauhan S., Jelen F., Sharina I., Martin E. (2012) The G-protein regulator LGN modulates the activity of the NO receptor soluble guanylate cyclase. Biochem. J. 446, 445–453 [DOI] [PMC free article] [PubMed] [Google Scholar]
26. Groves B., Abrahamsen H., Clingan H., Frantz M., Mavor L., Bailey J., Ma D. (2010) An inhibitory role of the G-protein regulator AGS3 in mTOR-dependent macroautophagy. PLoS One 5, e8877. [DOI] [PMC free article] [PubMed] [Google Scholar]
27. Zheng Z., Zhu H., Wan Q., Liu J., Xiao Z., Siderovski D. P., Du Q. (2010) LGN regulates mitotic spindle orientation during epithelial morphogenesis. J. Cell Biol. 189, 275–288 [DOI] [PMC free article] [PubMed] [Google Scholar]
28. Hofler C., Koelle M. R. (2011) AGS-3 alters Caenorhabditis elegans behavior after food deprivation via RIC-8 activation of the neural G protein Gαo. J. Neurosci. 31, 11553–11562 [DOI] [PMC free article] [PubMed] [Google Scholar]
29. Giguère P. M., Laroche G., Oestreich E. A., Duncan J. A., Siderovski D. P. (2012) Regulation of the subcellular localization of the G-protein subunit regulator GPSM3 through direct association with 14-3-3 protein. J. Biol. Chem. 287, 31270–31279 [DOI] [PMC free article] [PubMed] [Google Scholar]
30. Doherty D., Chudley A. E., Coghlan G., Ishak G. E., Innes A. M., Lemire E. G., Rogers R. C., Mhanni A. A., Phelps I. G., Jones S. J., Zhan S. H., Fejes A. P., Shahin H., Kanaan M., Akay H., Tekin M., FORGE Canada Consortium, Triggs-Raine B., Zelinski T. (2012) GPSM2 mutations cause the brain malformations and hearing loss in Chudley-McCullough syndrome. Am. J. Hum. Genet. 90, 1088–1093 [DOI] [PMC free article] [PubMed] [Google Scholar]
31. Tall G. G., Gilman A. G. (2005) Resistance to inhibitors of cholinesterase 8A catalyzes release of Gαi-GTP and nuclear mitotic apparatus protein (NuMA) from NuMA/LGN/Gαi-GDP complexes. Proc. Natl. Acad. Sci. U.S.A. 102, 16584–16589 [DOI] [PMC free article] [PubMed] [Google Scholar]
32. Thomas C. J., Tall G. G., Adhikari A., Sprang S. R. (2008) Ric-8A catalyzes guanine nucleotide exchange on Gαi1 bound to the GPR/GoLoco exchange inhibitor AGS3. J. Biol. Chem. 283, 23150–23160 [DOI] [PMC free article] [PubMed] [Google Scholar]
33. Oner S. S., Maher E. M., Gabay M., Tall G. G., Blumer J. B., Lanier S. M. (2013) Regulation of the G-protein regulatory-Gαi signaling complex by nonreceptor guanine nucleotide exchange factors. J. Biol. Chem. 288, 3003–3015 [DOI] [PMC free article] [PubMed] [Google Scholar]
34. Oner S. S., An N., Vural A., Breton B., Bouvier M., Blumer J. B., Lanier S. M. (2010) Regulation of the AGS3·Gαi signaling complex by a seven-transmembrane span receptor. J. Biol. Chem. 285, 33949–33958 [DOI] [PMC free article] [PubMed] [Google Scholar]
35. Oner S. S., Maher E. M., Breton B., Bouvier M., Blumer J. B. (2010) Receptor-regulated interaction of activator of G-protein signaling-4 and Gαi. J. Biol. Chem. 285, 20588–20594 [DOI] [PMC free article] [PubMed] [Google Scholar]
36. Vellano C. P., Maher E. M., Hepler J. R., Blumer J. B. (2011) G protein-coupled receptors and resistance to inhibitors of cholinesterase-8A (Ric-8A) both regulate the regulator of g protein signaling 14 RGS14·Gα_i1 complex in live cells. J. Biol. Chem. 286, 38659–38669 [DOI] [PMC free article] [PubMed] [Google Scholar]
37. Patterson G. H., Hirschberg K., Polishchuk R. S., Gerlich D., Phair R. D., Lippincott-Schwartz J. (2008) Transport through the Golgi apparatus by rapid partitioning within a two-phase membrane system. Cell 133, 1055–1067 [DOI] [PMC free article] [PubMed] [Google Scholar]
38. Vural A., Oner S., An N., Simon V., Ma D., Blumer J. B., Lanier S. M. (2010) Distribution of activator of G-protein signaling 3 within the aggresomal pathway. Role of specific residues in the tetratricopeptide repeat domain and differential regulation by the AGS3 binding partners Giα and mammalian inscuteable. Mol. Cell Biol. 30, 1528–1540 [DOI] [PMC free article] [PubMed] [Google Scholar]
39. Schneider C. A., Rasband W. S., Eliceiri K. W. (2012) NIH Image to ImageJ. 25 years of image analysis. Nat. Methods 9, 671–675 [DOI] [PMC free article] [PubMed] [Google Scholar]
40. Schindelin J., Arganda-Carreras I., Frise E., Kaynig V., Longair M., Pietzsch T., Preibisch S., Rueden C., Saalfeld S., Schmid B., Tinevez J. Y., White D. J., Hartenstein V., Eliceiri K., Tomancak P., Cardona A. (2012) Fiji. An open-source platform for biological-image analysis. Nat. Methods 9, 676–682 [DOI] [PMC free article] [PubMed] [Google Scholar]
41. Costes S. V., Daelemans D., Cho E. H., Dobbin Z., Pavlakis G., Lockett S. (2004) Automatic and quantitative measurement of protein-protein colocalization in live cells. Biophys. J. 86, 3993–4003 [DOI] [PMC free article] [PubMed] [Google Scholar]
42. Klein R. R., Bourdon D. M., Costales C. L., Wagner C. D., White W. L., Williams J. D., Hicks S. N., Sondek J., Thakker D. R. (2011) Direct activation of human phospholipase C by its well known inhibitor u73122. J. Biol. Chem. 286, 12407–12416 [DOI] [PMC free article] [PubMed] [Google Scholar]
43. Pizzinat N., Takesono A., Lanier S. M. (2001) Identification of a truncated form of the G-protein regulator AGS3 in heart that lacks the tetratricopeptide repeat domains. J. Biol. Chem. 276, 16601–16610 [DOI] [PubMed] [Google Scholar]
44. Cao X., Cismowski M. J., Sato M., Blumer J. B., Lanier S. M. (2004) Identification and characterization of AGS4. A protein containing three G-protein regulatory motifs that regulate the activation state of Giα. J. Biol. Chem. 279, 27567–27574 [DOI] [PubMed] [Google Scholar]
45. Stow J. L., de Almeida J. B., Narula N., Holtzman E. J., Ercolani L., Ausiello D. A. (1991) A heterotrimeric G protein, Gαi-3, on Golgi membranes regulates the secretion of a heparan sulfate proteoglycan in LLC-PK1 epithelial cells. J. Cell Biol. 114, 1113–1124 [DOI] [PMC free article] [PubMed] [Google Scholar]
46. Leyte A., Barr F. A., Kehlenbach R. H., Huttner W. B. (1992) Multiple trimeric G-proteins on the trans-Golgi network exert stimulatory and inhibitory effects on secretory vesicle formation. EMBO J. 11, 4795–4804 [DOI] [PMC free article] [PubMed] [Google Scholar]
47. Schwaninger R., Plutner H., Bokoch G. M., Balch W. E. (1992) Multiple GTP-binding proteins regulate vesicular transport from the ER to Golgi membranes. J. Cell Biol. 119, 1077–1096 [DOI] [PMC free article] [PubMed] [Google Scholar]
48. Jamora C., Takizawa P. A., Zaarour R. F., Denesvre C., Faulkner D. J., Malhotra V. (1997) Regulation of Golgi structure through heterotrimeric G proteins. Cell 91, 617–626 [DOI] [PubMed] [Google Scholar]
49. Jamora C., Yamanouye N., Van Lint J., Laudenslager J., Vandenheede J. R., Faulkner D. J., Malhotra V. (1999) Gβγ-mediated regulation of Golgi organization is through the direct activation of protein kinase D. Cell 98, 59–68 [DOI] [PubMed] [Google Scholar]
50. Yamaguchi T., Nagahama M., Itoh H., Hatsuzawa K., Tani K., Tagaya M. (2000) Regulation of the Golgi structure by the α subunits of heterotrimeric G proteins. FEBS Lett. 470, 25–28 [DOI] [PubMed] [Google Scholar]
51. Denker S. P., McCaffery J. M., Palade G. E., Insel P. A., Farquhar M. G. (1996) Differential distribution of α subunits and βγ subunits of heterotrimeric G proteins on Golgi membranes of the exocrine pancreas. J. Cell Biol. 133, 1027–1040 [DOI] [PMC free article] [PubMed] [Google Scholar]
52. Wilson B. S., Palade G. E., Farquhar M. G. (1993) Endoplasmic reticulum-through-Golgi transport assay based on O-glycosylation of native glycophorin in permeabilized erythroleukemia cells. Role for Gi3. Proc. Natl. Acad. Sci. U.S.A. 90, 1681–1685 [DOI] [PMC free article] [PubMed] [Google Scholar]
53. Chatterjee T. K., Fisher R. A. (2000) Cytoplasmic, nuclear, and Golgi localization of RGS proteins. Evidence for N-terminal and RGS domain sequences as intracellular targeting motifs. J. Biol. Chem. 275, 24013–24021 [DOI] [PubMed] [Google Scholar]
54. Akgoz M., Kalyanaraman V., Gautam N. (2004) Receptor-mediated reversible translocation of the G protein βγ complex from the plasma membrane to the Golgi complex. J. Biol. Chem. 279, 51541–51544 [DOI] [PubMed] [Google Scholar]
55. Azpiazu I., Akgoz M., Kalyanaraman V., Gautam N. (2006) G protein βγ11 complex translocation is induced by Gi, Gq, and Gs coupling receptors and is regulated by the α subunit type. Cell. Signal. 18, 1190–1200 [DOI] [PMC free article] [PubMed] [Google Scholar]
56. Akgoz M., Kalyanaraman V., Gautam N. (2006) G protein βγ complex translocation from plasma membrane to Golgi complex is influenced by receptor γ subunit interaction. Cell. Signal. 18, 1758–1768 [DOI] [PMC free article] [PubMed] [Google Scholar]
57. Saini D. K., Karunarathne W. K., Angaswamy N., Saini D., Cho J. H., Kalyanaraman V., Gautam N. (2010) Regulation of Golgi structure and secretion by receptor-induced G protein βγ complex translocation. Proc. Natl. Acad. Sci. U.S.A. 107, 11417–11422 [DOI] [PMC free article] [PubMed] [Google Scholar]
58. Hewavitharana T., Wedegaertner P. B. (2012) Non-canonical signaling and localizations of heterotrimeric G proteins. Cell. Signal. 24, 25–34 [DOI] [PMC free article] [PubMed] [Google Scholar]
59. Díaz Anel A. M., Malhotra V. (2005) PKCη is required for β1γ2/β3γ2- and PKD-mediated transport to the cell surface and the organization of the Golgi apparatus. J. Cell Biol. 169, 83–91 [DOI] [PMC free article] [PubMed] [Google Scholar]
60. Díaz Añel A. M. (2007) Phospholipase C β3 is a key component in the Gβγ/PKCη/PKD-mediated regulation of trans-Golgi network to plasma membrane transport. Biochem. J. 406, 157–165 [DOI] [PMC free article] [PubMed] [Google Scholar]
61. Irannejad R., Wedegaertner P. B. (2010) Regulation of constitutive cargo transport from the trans-Golgi network to plasma membrane by Golgi-localized G protein βγ subunits. J. Biol. Chem. 285, 32393–32404 [DOI] [PMC free article] [PubMed] [Google Scholar]
62. Gibson S. K., Gilman A. G. (2006) Giα and Gβ subunits both define selectivity of G protein activation by α2-adrenergic receptors. Proc. Natl. Acad. Sci. U.S.A. 103, 212–217 [DOI] [PMC free article] [PubMed] [Google Scholar]
63. Blumer J. B., Bernard M. L., Peterson Y. K., Nezu J., Chung P., Dunican D. J., Knoblich J. A., Lanier S. M. (2003) Interaction of activator of G-protein signaling 3 (AGS3) with LKB1, a serine/threonine kinase involved in cell polarity and cell cycle progression: phosphorylation of the G-protein regulatory (GPR) motif as a regulatory mechanism for the interaction of GPR motifs with Giα. J. Biol. Chem. 278, 23217–23220 [DOI] [PubMed] [Google Scholar]

[B1] 1. Blumer J. B., Smrcka A. V., Lanier S. M. (2007) Mechanistic pathways and biological roles for receptor-independent activators of G-protein signaling. Pharmacol. Ther. 113, 488–506 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B2] 2. Hollinger S., Hepler J. R. (2002) Cellular regulation of RGS proteins. Modulators and integrators of G protein signaling. Pharmacol. Rev. 54, 527–559 [DOI] [PubMed] [Google Scholar]

[B3] 3. Regner K. R., Nozu K., Lanier S. M., Blumer J. B., Avner E. D., Sweeney W. E., Jr., Park F. (2011) Loss of activator of G-protein signaling 3 impairs renal tubular regeneration following acute kidney injury in rodents. FASEB J. 25, 1844–1855 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B4] 4. Sato M., Jiao Q., Honda T., Kurotani R., Toyota E., Okumura S., Takeya T., Minamisawa S., Lanier S. M., Ishikawa Y. (2009) Activator of G protein signaling 8 (AGS8) is required for hypoxia-induced apoptosis of cardiomyocytes. Role of G βγ and connexin 43 (CX43). J. Biol. Chem. 284, 31431–31440 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B5] 5. Blumer J. B., Sadik Oner S., Lanier S. M. (2012) Acta Physiol. 204, 202–218 [DOI] [PubMed] [Google Scholar]

[B6] 6. Kimple A. J., Bosch D. E., Giguère P. M., Siderovski D. P. (2011) Regulators of G-protein signaling and their Gα substrates. Promises and challenges in their use as drug discovery targets. Pharmacol. Rev. 63, 728–749 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B7] 7. Tall G. G., Krumins A. M., Gilman A. G. (2003) Mammalian Ric-8A (synembryn) is a heterotrimeric Gα protein guanine nucleotide exchange factor. J. Biol. Chem. 278, 8356–8362 [DOI] [PubMed] [Google Scholar]

[B8] 8. Garcia-Marcos M., Kietrsunthorn P. S., Pavlova Y., Adia M. A., Ghosh P., Farquhar M. G. (2012) Functional characterization of the guanine nucleotide exchange factor (GEF) motif of GIV protein reveals a threshold effect in signaling. Proc. Natl. Acad. Sci. U.S.A. 109, 1961–1966 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B9] 9. Lee M. J., Dohlman H. G. (2008) Coactivation of G protein signaling by cell-surface receptors and an intracellular exchange factor. Curr. Biol. 18, 211–215 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B10] 10. Sato M., Cismowski M. J., Toyota E., Smrcka A. V., Lucchesi P. A., Chilian W. M., Lanier S. M. (2006) Identification of a receptor-independent activator of G protein signaling (AGS8) in ischemic heart and its interaction with Gβγ. Proc. Natl. Acad. Sci. U.S.A. 103, 797–802 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B11] 11. Sato M., Hiraoka M., Suzuki H., Bai Y., Kurotani R., Yokoyama U., Okumura S., Cismowski M. J., Lanier S. M., Ishikawa Y. (2011) Identification of transcription factor E3 (TFE3) as a receptor-independent activator of Gα16. Gene regulation by nuclear Gα subunit and its activator. J. Biol. Chem. 286, 17766–17776 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B12] 12. Takesono A., Cismowski M. J., Ribas C., Bernard M., Chung P., Hazard S., 3rd, Duzic E., Lanier S. M. (1999) Receptor-independent activators of heterotrimeric G-protein signaling pathways. J. Biol. Chem. 274, 33202–33205 [DOI] [PubMed] [Google Scholar]

[B13] 13. Ponting C. P. (1999) Raf-like Ras/Rap-binding domains in RGS12- and still-life-like signalling proteins. J. Mol. Med. 77, 695–698 [DOI] [PubMed] [Google Scholar]

[B14] 14. Siderovski D. P., Diversé-Pierluissi M., De Vries L. (1999) The GoLoco motif. A Gαi/o binding motif and potential guanine-nucleotide exchange factor. Trends Biochem. Sci. 24, 340–341 [DOI] [PubMed] [Google Scholar]

[B15] 15. Blumer J. B., Lord K., Saunders T. L., Pacchioni A., Black C., Lazartigues E., Varner K. J., Gettys T. W., Lanier S. M. (2008) Activator of G protein signaling 3 null mice. I. Unexpected alterations in metabolic and cardiovascular function. Endocrinology 149, 3842–3849 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B16] 16. Bowers M. S., Hopf F. W., Chou J. K., Guillory A. M., Chang S. J., Janak P. H., Bonci A., Diamond I. (2008) Nucleus accumbens AGS3 expression drives ethanol seeking through Gβγ. Proc. Natl. Acad. Sci. U.S.A. 105, 12533–12538 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B17] 17. Bowers M. S., McFarland K., Lake R. W., Peterson Y. K., Lapish C. C., Gregory M. L., Lanier S. M., Kalivas P. W. (2004) Activator of G protein signaling 3. A gatekeeper of cocaine sensitization and drug seeking. Neuron 42, 269–281 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B18] 18. Groves B., Gong Q., Xu Z., Huntsman C., Nguyen C., Li D., Ma D. (2007) A specific role of AGS3 in the surface expression of plasma membrane proteins. Proc. Natl. Acad. Sci. U.S.A. 104, 18103–18108 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B19] 19. Nadella R., Blumer J. B., Jia G., Kwon M., Akbulut T., Qian F., Sedlic F., Wakatsuki T., Sweeney W. E., Jr., Wilson P. D., Lanier S. M., Park F. (2010) Activator of G protein signaling 3 promotes epithelial cell proliferation in PKD. J. Am. Soc. Nephrol. 21, 1275–1280 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B20] 20. Yao L., McFarland K., Fan P., Jiang Z., Inoue Y., Diamond I. (2005) Activator of G protein signaling 3 regulates opiate activation of protein kinase A signaling and relapse of heroin-seeking behavior. Proc. Natl. Acad. Sci. U.S.A. 102, 8746–8751 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B21] 21. Yao L., McFarland K., Fan P., Jiang Z., Ueda T., Diamond I. (2006) Adenosine A2a blockade prevents synergy between μ-opiate and cannabinoid CB1 receptors and eliminates heroin-seeking behavior in addicted rats. Proc. Natl. Acad. Sci. U.S.A. 103, 7877–7882 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B22] 22. Willard F. S., Zheng Z., Guo J., Digby G. J., Kimple A. J., Conley J. M., Johnston C. A., Bosch D., Willard M. D., Watts V. J., Lambert N. A., Ikeda S. R., Du Q., Siderovski D. P. (2008) A point mutation to Gαi selectively blocks GoLoco motif binding. direct evidence for Gα·GoLoco complexes in mitotic spindle dynamics. J. Biol. Chem. 283, 36698–36710 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B23] 23. Pattingre S., De Vries L., Bauvy C., Chantret I., Cluzeaud F., Ogier-Denis E., Vandewalle A., Codogno P. (2003) The G-protein regulator AGS3 controls an early event during macroautophagy in human intestinal HT-29 cells. J. Biol. Chem. 278, 20995–21002 [DOI] [PubMed] [Google Scholar]

[B24] 24. Garcia-Marcos M., Ear J., Farquhar M. G., Ghosh P. (2011) A GDI (AGS3) and a GEF (GIV) regulate autophagy by balancing G protein activity and growth factor signals. Mol. Biol. Cell 22, 673–686 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B25] 25. Chauhan S., Jelen F., Sharina I., Martin E. (2012) The G-protein regulator LGN modulates the activity of the NO receptor soluble guanylate cyclase. Biochem. J. 446, 445–453 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B26] 26. Groves B., Abrahamsen H., Clingan H., Frantz M., Mavor L., Bailey J., Ma D. (2010) An inhibitory role of the G-protein regulator AGS3 in mTOR-dependent macroautophagy. PLoS One 5, e8877. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B27] 27. Zheng Z., Zhu H., Wan Q., Liu J., Xiao Z., Siderovski D. P., Du Q. (2010) LGN regulates mitotic spindle orientation during epithelial morphogenesis. J. Cell Biol. 189, 275–288 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B28] 28. Hofler C., Koelle M. R. (2011) AGS-3 alters Caenorhabditis elegans behavior after food deprivation via RIC-8 activation of the neural G protein Gαo. J. Neurosci. 31, 11553–11562 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B29] 29. Giguère P. M., Laroche G., Oestreich E. A., Duncan J. A., Siderovski D. P. (2012) Regulation of the subcellular localization of the G-protein subunit regulator GPSM3 through direct association with 14-3-3 protein. J. Biol. Chem. 287, 31270–31279 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B30] 30. Doherty D., Chudley A. E., Coghlan G., Ishak G. E., Innes A. M., Lemire E. G., Rogers R. C., Mhanni A. A., Phelps I. G., Jones S. J., Zhan S. H., Fejes A. P., Shahin H., Kanaan M., Akay H., Tekin M., FORGE Canada Consortium, Triggs-Raine B., Zelinski T. (2012) GPSM2 mutations cause the brain malformations and hearing loss in Chudley-McCullough syndrome. Am. J. Hum. Genet. 90, 1088–1093 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B31] 31. Tall G. G., Gilman A. G. (2005) Resistance to inhibitors of cholinesterase 8A catalyzes release of Gαi-GTP and nuclear mitotic apparatus protein (NuMA) from NuMA/LGN/Gαi-GDP complexes. Proc. Natl. Acad. Sci. U.S.A. 102, 16584–16589 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B32] 32. Thomas C. J., Tall G. G., Adhikari A., Sprang S. R. (2008) Ric-8A catalyzes guanine nucleotide exchange on Gαi1 bound to the GPR/GoLoco exchange inhibitor AGS3. J. Biol. Chem. 283, 23150–23160 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B33] 33. Oner S. S., Maher E. M., Gabay M., Tall G. G., Blumer J. B., Lanier S. M. (2013) Regulation of the G-protein regulatory-Gαi signaling complex by nonreceptor guanine nucleotide exchange factors. J. Biol. Chem. 288, 3003–3015 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B34] 34. Oner S. S., An N., Vural A., Breton B., Bouvier M., Blumer J. B., Lanier S. M. (2010) Regulation of the AGS3·Gαi signaling complex by a seven-transmembrane span receptor. J. Biol. Chem. 285, 33949–33958 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B35] 35. Oner S. S., Maher E. M., Breton B., Bouvier M., Blumer J. B. (2010) Receptor-regulated interaction of activator of G-protein signaling-4 and Gαi. J. Biol. Chem. 285, 20588–20594 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B36] 36. Vellano C. P., Maher E. M., Hepler J. R., Blumer J. B. (2011) G protein-coupled receptors and resistance to inhibitors of cholinesterase-8A (Ric-8A) both regulate the regulator of g protein signaling 14 RGS14·Gα_i1 complex in live cells. J. Biol. Chem. 286, 38659–38669 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B37] 37. Patterson G. H., Hirschberg K., Polishchuk R. S., Gerlich D., Phair R. D., Lippincott-Schwartz J. (2008) Transport through the Golgi apparatus by rapid partitioning within a two-phase membrane system. Cell 133, 1055–1067 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B38] 38. Vural A., Oner S., An N., Simon V., Ma D., Blumer J. B., Lanier S. M. (2010) Distribution of activator of G-protein signaling 3 within the aggresomal pathway. Role of specific residues in the tetratricopeptide repeat domain and differential regulation by the AGS3 binding partners Giα and mammalian inscuteable. Mol. Cell Biol. 30, 1528–1540 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B39] 39. Schneider C. A., Rasband W. S., Eliceiri K. W. (2012) NIH Image to ImageJ. 25 years of image analysis. Nat. Methods 9, 671–675 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B40] 40. Schindelin J., Arganda-Carreras I., Frise E., Kaynig V., Longair M., Pietzsch T., Preibisch S., Rueden C., Saalfeld S., Schmid B., Tinevez J. Y., White D. J., Hartenstein V., Eliceiri K., Tomancak P., Cardona A. (2012) Fiji. An open-source platform for biological-image analysis. Nat. Methods 9, 676–682 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B41] 41. Costes S. V., Daelemans D., Cho E. H., Dobbin Z., Pavlakis G., Lockett S. (2004) Automatic and quantitative measurement of protein-protein colocalization in live cells. Biophys. J. 86, 3993–4003 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B42] 42. Klein R. R., Bourdon D. M., Costales C. L., Wagner C. D., White W. L., Williams J. D., Hicks S. N., Sondek J., Thakker D. R. (2011) Direct activation of human phospholipase C by its well known inhibitor u73122. J. Biol. Chem. 286, 12407–12416 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B43] 43. Pizzinat N., Takesono A., Lanier S. M. (2001) Identification of a truncated form of the G-protein regulator AGS3 in heart that lacks the tetratricopeptide repeat domains. J. Biol. Chem. 276, 16601–16610 [DOI] [PubMed] [Google Scholar]

[B44] 44. Cao X., Cismowski M. J., Sato M., Blumer J. B., Lanier S. M. (2004) Identification and characterization of AGS4. A protein containing three G-protein regulatory motifs that regulate the activation state of Giα. J. Biol. Chem. 279, 27567–27574 [DOI] [PubMed] [Google Scholar]

[B45] 45. Stow J. L., de Almeida J. B., Narula N., Holtzman E. J., Ercolani L., Ausiello D. A. (1991) A heterotrimeric G protein, Gαi-3, on Golgi membranes regulates the secretion of a heparan sulfate proteoglycan in LLC-PK1 epithelial cells. J. Cell Biol. 114, 1113–1124 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B46] 46. Leyte A., Barr F. A., Kehlenbach R. H., Huttner W. B. (1992) Multiple trimeric G-proteins on the trans-Golgi network exert stimulatory and inhibitory effects on secretory vesicle formation. EMBO J. 11, 4795–4804 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B47] 47. Schwaninger R., Plutner H., Bokoch G. M., Balch W. E. (1992) Multiple GTP-binding proteins regulate vesicular transport from the ER to Golgi membranes. J. Cell Biol. 119, 1077–1096 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B48] 48. Jamora C., Takizawa P. A., Zaarour R. F., Denesvre C., Faulkner D. J., Malhotra V. (1997) Regulation of Golgi structure through heterotrimeric G proteins. Cell 91, 617–626 [DOI] [PubMed] [Google Scholar]

[B49] 49. Jamora C., Yamanouye N., Van Lint J., Laudenslager J., Vandenheede J. R., Faulkner D. J., Malhotra V. (1999) Gβγ-mediated regulation of Golgi organization is through the direct activation of protein kinase D. Cell 98, 59–68 [DOI] [PubMed] [Google Scholar]

[B50] 50. Yamaguchi T., Nagahama M., Itoh H., Hatsuzawa K., Tani K., Tagaya M. (2000) Regulation of the Golgi structure by the α subunits of heterotrimeric G proteins. FEBS Lett. 470, 25–28 [DOI] [PubMed] [Google Scholar]

[B51] 51. Denker S. P., McCaffery J. M., Palade G. E., Insel P. A., Farquhar M. G. (1996) Differential distribution of α subunits and βγ subunits of heterotrimeric G proteins on Golgi membranes of the exocrine pancreas. J. Cell Biol. 133, 1027–1040 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B52] 52. Wilson B. S., Palade G. E., Farquhar M. G. (1993) Endoplasmic reticulum-through-Golgi transport assay based on O-glycosylation of native glycophorin in permeabilized erythroleukemia cells. Role for Gi3. Proc. Natl. Acad. Sci. U.S.A. 90, 1681–1685 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B53] 53. Chatterjee T. K., Fisher R. A. (2000) Cytoplasmic, nuclear, and Golgi localization of RGS proteins. Evidence for N-terminal and RGS domain sequences as intracellular targeting motifs. J. Biol. Chem. 275, 24013–24021 [DOI] [PubMed] [Google Scholar]

[B54] 54. Akgoz M., Kalyanaraman V., Gautam N. (2004) Receptor-mediated reversible translocation of the G protein βγ complex from the plasma membrane to the Golgi complex. J. Biol. Chem. 279, 51541–51544 [DOI] [PubMed] [Google Scholar]

[B55] 55. Azpiazu I., Akgoz M., Kalyanaraman V., Gautam N. (2006) G protein βγ11 complex translocation is induced by Gi, Gq, and Gs coupling receptors and is regulated by the α subunit type. Cell. Signal. 18, 1190–1200 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B56] 56. Akgoz M., Kalyanaraman V., Gautam N. (2006) G protein βγ complex translocation from plasma membrane to Golgi complex is influenced by receptor γ subunit interaction. Cell. Signal. 18, 1758–1768 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B57] 57. Saini D. K., Karunarathne W. K., Angaswamy N., Saini D., Cho J. H., Kalyanaraman V., Gautam N. (2010) Regulation of Golgi structure and secretion by receptor-induced G protein βγ complex translocation. Proc. Natl. Acad. Sci. U.S.A. 107, 11417–11422 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B58] 58. Hewavitharana T., Wedegaertner P. B. (2012) Non-canonical signaling and localizations of heterotrimeric G proteins. Cell. Signal. 24, 25–34 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B59] 59. Díaz Anel A. M., Malhotra V. (2005) PKCη is required for β1γ2/β3γ2- and PKD-mediated transport to the cell surface and the organization of the Golgi apparatus. J. Cell Biol. 169, 83–91 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B60] 60. Díaz Añel A. M. (2007) Phospholipase C β3 is a key component in the Gβγ/PKCη/PKD-mediated regulation of trans-Golgi network to plasma membrane transport. Biochem. J. 406, 157–165 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B61] 61. Irannejad R., Wedegaertner P. B. (2010) Regulation of constitutive cargo transport from the trans-Golgi network to plasma membrane by Golgi-localized G protein βγ subunits. J. Biol. Chem. 285, 32393–32404 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B62] 62. Gibson S. K., Gilman A. G. (2006) Giα and Gβ subunits both define selectivity of G protein activation by α2-adrenergic receptors. Proc. Natl. Acad. Sci. U.S.A. 103, 212–217 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B63] 63. Blumer J. B., Bernard M. L., Peterson Y. K., Nezu J., Chung P., Dunican D. J., Knoblich J. A., Lanier S. M. (2003) Interaction of activator of G-protein signaling 3 (AGS3) with LKB1, a serine/threonine kinase involved in cell polarity and cell cycle progression: phosphorylation of the G-protein regulatory (GPR) motif as a regulatory mechanism for the interaction of GPR motifs with Giα. J. Biol. Chem. 278, 23217–23220 [DOI] [PubMed] [Google Scholar]

PERMALINK

Translocation of Activator of G-protein Signaling 3 to the Golgi Apparatus in Response to Receptor Activation and Its Effect on the trans-Golgi Network^*

Sukru S Oner

Ali Vural

Stephen M Lanier

Abstract

Introduction